Gossamer Bio’s (GOSS) Outperform Rating Reaffirmed at Wedbush

Wedbush reissued their outperform rating on shares of Gossamer Bio (NASDAQ:GOSS) in a research report report published on Friday,Benzinga reports. Wedbush currently has a $4.00 target price on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Gossamer Bio in a report on Thursday, January 30th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $9.20.

Gossamer Bio Trading Up 11.5 %

GOSS opened at $1.45 on Friday. Gossamer Bio has a 52 week low of $0.50 and a 52 week high of $1.55. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64. The business has a fifty day simple moving average of $1.13 and a 200-day simple moving average of $0.97. The firm has a market cap of $328.58 million, a P/E ratio of -4.53 and a beta of 1.86.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Tuesday, March 18th. The company reported ($0.15) EPS for the quarter, meeting analysts’ consensus estimates of ($0.15). On average, equities analysts expect that Gossamer Bio will post -0.28 earnings per share for the current year.

Institutional Investors Weigh In On Gossamer Bio

A number of hedge funds have recently bought and sold shares of the stock. Graham Capital Management L.P. acquired a new position in shares of Gossamer Bio during the fourth quarter worth about $32,000. US Bancorp DE purchased a new position in Gossamer Bio in the third quarter worth approximately $39,000. Fullcircle Wealth LLC acquired a new position in Gossamer Bio during the 4th quarter worth approximately $43,000. GSA Capital Partners LLP purchased a new stake in shares of Gossamer Bio in the 3rd quarter valued at approximately $67,000. Finally, Velan Capital Investment Management LP purchased a new stake in shares of Gossamer Bio in the 4th quarter valued at approximately $68,000. Institutional investors and hedge funds own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.